Trombosit dağılım genişliği lenfosit oranı, metastatik böbrek hücreli kanserde sağkalımı öngörmede yeni bir biyobelirteç olabilir mi?

Year 2024, Volume: 15 Issue: 2, 214 - 220, 01.07.2024

Esra Zeynelgil , Hayriye Şahinli , Özlem Doğan , Perihan Perkin , Yakup Duzkopru

https://doi.org/10.18663/tjcl.1460375

Abstract

Amaç: Tirozin kinaz inhibitörü kullanan metastatik böbrek hücreli kanserli hastalarda trombosit dağılım genişliğinin lenfosit oranı (PDWLR)’nın prognostik değeri net olarak bilinmemektedir. Bu çalışmada amacımız PDWLR ‘nin metastatik renal kanserli hastalarda prognostik önemini değerlendirmektir.
Gereç ve Yöntemler: Bu retrospektif çalışmaya Ocak 2010-Aralık 2020 tarihleri arasında halen Tirozin kinaz inhibitörü tedavisi alan 66 metastatik renal hücreli kanserli hasta dahil edildi .Cut off değeri ROC curve analizi ile tesbit edildi. RDWLR için en iyi cut off değeri 9.33 olarak tesbit edildi.RDWLR için sensivite ve spesivite sırasıyla %55.3, %57.9 idi. PDWLR ve klinikopatolojik değişkenler arasındaki ilişkiyi değerlendirmek için ki kare ve Fisher exact testleri kullanıldı. Multivariate analiz için Cox oransal hazards modeli kullanıldı.
Sonuç: TKİ kullanan metastaik rcc hastalarında tedavi esnasında bakılan PDWLR ‘nin OS tahmin etmede önemli prognostik faktör olduğu Pfs üzerine anlamlı etkisinin olmadığı tespit edilmiştir.Metastatik renal hücreli kanserli hastalarda , PDWLR düzeyi prognostik bir marker olarak kullanılabilir, ancak daha fazla hasta sayısı ile yapılacak çalışmalara ihtiyaç vardır.

Keywords

metastatik renal hücreli kanser, PDWLR, OS

Project Number

Ankara Dışkapı Eğitim Araştırma Hastanesi Klinik Araştırmalar Etik Kurulu Karar Tarihi: 28.06.2021 Karar no: 114/17

Can platelet distribution width lymphocyte ratio be a novel biomarker for predicting survival in metastatic renal cell cancer?

Abstract

Aim: The prognostic value of platelet distribution width to lymphocyte ratio (PDWLR) in patients with metastatic renal cell cancer using tyrosine kinase inhibitors is not clearly known. Our aim in this study is to evaluate the prognostic importance of PDWLR in patients with metastatic renal cancer.

Meterial and results: This retrospective study included 66 patients with metastatic renal cell cancer who were currently receiving Tyrosine kinase inhibitor treatment between January 2010 and December 2020. The cut off value was determined by ROC curve analysis. The best cut-off value for RDWLR was determined as 9.33. Sensitivity and specificity for RDWLR were 55.3% and 57.9%, respectively. Chi-square and Fisher exact tests were used to evaluate the relationship between PDWLR and clinicopathological variables. Cox proportional hazards model was used for multivariate analysis.
Conclusion: It has been determined that PDWLR measured during treatment in metastatic RCC patients using TKIs has no significant effect on Pfs, which is an important prognostic factor in predicting OS. In patients with metastatic renal cell cancer, PDWLR level can be used as a prognostic marker, but studies with a larger number of patients are needed.

Keywords

metastatic renal cell cancer, PDWLR, OS

Project Number

Ankara Dışkapı Eğitim Araştırma Hastanesi Klinik Araştırmalar Etik Kurulu Karar Tarihi: 28.06.2021 Karar no: 114/17

References

• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010 Mar 19;140(6):883-99. doi: 10.1016/j.cell.2010.01.025. PMID: 20303878; PMCID: PMC2866629.
• Chang Y, Fu Q, Xu L, Zhou L, Liu Z, Yang Y, Lin Z, Xu J. Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma. Tumour Biol. 2016 Apr;37(4):4613-20. doi: 10.1007/s13277-015-4300-7. Epub 2015 Oct 27. PMID: 26508025.
• Shao Y, Wu B, Jia W, Zhang Z, Chen Q, Wang D. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. BMC Urol. 2020 Jul 6;20(1):90. doi: 10.1186/s12894-020-00665-8. PMID: 32631294; PMCID: PMC7339475.
• Cao J, Zhu X, Zhao X, Li XF, Xu R. Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016 Jul 1;11(7):e0158770. doi: 10.1371/journal.pone.0158770. PMID: 27368058; PMCID: PMC4930176.
• Nurden AT. Platelets, inflammation and tissue regeneration. ThrombHaemost. 2011 May;105 Suppl 1:S13-33. doi: 10.1160/THS10-11-0720. Epub 2011 Apr 11. PMID: 21479340.
• Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin ThrombHemost. 2014 Apr;40(3):296-305. doi: 10.1055/s-0034-1370767. Epub 2014 Mar 3. PMID: 24590421.
• Tsujino T, Komura K, Ichihashi A, Tsutsumi T, Matsunaga T, Yoshikawa Y, Maenosono R, Okita K, Takai T, Oide R, Minami K, Uehara H, Taniguchi K, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma. Oncotarget. 2017 Nov 25;8(66):110311-110325. doi: 10.18632/oncotarget.22688. PMID: 29299149; PMCID: PMC5746384.
• Wang J, Liu Y, Zhang N, Li X, Xin P, Bi J, Kong C. Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer. Oncotarget. 2017 Aug 10;8(41):70874-70882. doi: 10.18632/oncotarget.20147. PMID: 29050328; PMCID: PMC5642603.
• Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013 Mar 5;108(4):901-7. doi: 10.1038/bjc.2013.28. Epub 2013 Feb 5. PMID: 23385728; PMCID: PMC3590665.
• Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010 Sep;184(3):873-8. doi: 10.1016/j.juro.2010.05.028. PMID: 20643463.
• Maráz A, Cserháti A, Uhercsák G, Szilágyi É, Varga Z, Révész J, Kószó R, Varga L, Kahán Z. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BMC Cancer. 2018 Mar 15;18(1):296. doi: 10.1186/s12885-018-4209-9. PMID: 29544452; PMCID: PMC5856318.
• Semeniuk-Wojtaś A, Lubas A, Stec R, Syryło T, Niemczyk S, Szczylik C. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis. Clin Genitourin Cancer. 2018 Jun;16(3):e685-e693. doi: 10.1016/j.clgc.2018.01.010. Epub 2018 Feb 2. PMID: 29454639.
• Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012 Jan;48(2):202-8. doi: 10.1016/j.ejca.2011.09.001. Epub 2011 Oct 19. PMID: 22018713; PMCID: PMC3483077.
• Gunduz S, Mutlu H, Tural D, Yıldız Ö, Uysal M, Coskun HS, Bozcuk H. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia Pac J Clin Oncol. 2015 Dec;11(4):288-92. doi: 10.1111/ajco.12358. Epub 2015 Apr 14. PMID: 25871569.
• Chrom P, Stec R, Semeniuk-Wojtas A, Bodnar L, Spencer NJ, Szczylik C. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2016 Oct;14(5):457-464. doi: 10.1016/j.clgc.2016.02.005. Epub 2016 Feb 21. PMID: 26980234.
• Park TJ, Cho YH, Chung HS, Hwang EC, Jung SH, Hwang JE, Bae WK, Kim JW, Heo SH, Hur YH, Jung SI, Kwon DD. Prognostic significance of platelet-lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer. Springerplus. 2016 Oct 28;5(1):1889. doi: 10.1186/s40064-016-3592-4. PMID: 27843746; PMCID: PMC5084140.
• Huszno J, Kołosza Z, Mrochem-Kwarciak J, Telka E, Jochymek B, Miszczyk L. Role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio and platelets in prognosis of patients with prostate cancer. Oncol Lett. 2022 Jul 8;24(3):305. doi: 10.3892/ol.2022.13425. PMID: 35949621; PMCID: PMC9353225.
• Aktepe OH, Güner G, Güven DC, Şahin TK, Ardıç FS, Yüce D, Yalçın Ş, Erman M. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma. Turk J Med Sci. 2021 Apr 30;51(2):757-765. doi: 10.3906/sag-2009-75. PMID: 33350295; PMCID: PMC8203127.
• Awadh NI, Gorial FI, Hammadi RA, Ibrahim MK, Majeed SH, Mohammed MJ. Mean platelet volume to lymphocyte ratio and platelet distribution width to lymphocyte ratio in Iraqi patients diagnosed with systemic lupus erythematosus. Reumatologia. 2022;60(3):173-182. doi: 10.5114/reum.2022.117837. Epub 2022 Jul 13. PMID: 35875718; PMCID: PMC9301666.
• Köse A, Akdeniz A, Babus SB, Göçmen M, Temel GO. The Usefulness of Platelet Distribution Width and Platelet Distribution Width to Lymphocyte Ratio in Predicting Severity and Outcomes in Patients with Snakebite. Wilderness Environ Med. 2021 Sep;32(3):284-292. doi: 10.1016/j.wem.2021.03.006. Epub 2021 Jun 23. PMID: 34172373.